Novel Peptide-Based Immunotherapy Holds Promise for Peanut Allergy
PVX108, a peptide-based immunotherapy in development for the treatment of peanut allergy, demonstrated a favorable safety profile.
PVX108, a peptide-based immunotherapy in development for the treatment of peanut allergy, demonstrated a favorable safety profile.
Children with asthma who received montelukast had no increased risk for neuropsychiatric disease compared with children who did not receive the treatment.
The immune response to vaccinations is lower in children who are obese compared with nonobese children, as indicated by lower vaccine titers.
Researchers sought to determine whether a multidisciplinary SABA reduction program would significantly increase the percentage of patients who reached an AMR ≥0.5.
This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019. SAN FRANCISCO — Patients…
Patients who were actively treated with AR101, an investigational oral biologic with a characterized peanut protein profile, reported accidental exposure to peanut less often, had fewer associated adverse events, and required less rescue medication compared with placebo.
Quality of sleep significantly improved in patients with allergic rhinitis who were treated with the house dust mite (HDM) sublingual immunotherapy-tablet (12 SQ-HDM), according to a post hoc analysis.
People who take gastric acid suppression agents have a high risk of requiring subsequent anti-allergy drugs.
Asthma may be well-controlled in children with morbid obesity with participation in the Breathmobile.
Asthma is linked to osteopenia, osteoporosis, osteomalacia, and pathological fractures in the United States.